InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
0
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-24.5%
Across 3 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the detailed record of transactions filed by Mammen Mathai, Director. Director active across 2 companies, notably 10x Genomics, Inc.. Aggregated, 9 reports have been recorded. History available since 11 June 2021. The latest transaction was filed on 11 June 2024 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations9 total
8,649 shares0Class A Common StockSEC:0001610717-24-000326:0
1,865 shares0Class A Common StockSEC:0001610717-23-000173:0
200,000 shares@ US$1.16100.0% of flowClass A Common StockSEC:0001610717-23-000035:0
2,120 shares0Class A Common StockSEC:0001567619-22-013119:0
7,740 shares0Common StockSEC:0001225208-22-002372:0
7,740 shares0Common StockSEC:0001225208-22-002372
7,418 shares0Common StockSEC:0001225208-22-002220:0
625 shares0Class A Common StockSEC:0001209191-21-040689
625 shares0Class A Common StockSEC:0001209191-21-040689:0
9 of 9 declarations
About Mammen Mathai
Mathai Mammen is a Board Member and Executive Vice President of Pharmaceuticals and R&D at 10x Genomics, Inc. and JOHNSON & JOHNSON. He plays an essential role in the research and innovation strategy of these companies.
